Advances in Vaccine Development Against Sporotrichosis

AbstractPurpose of ReviewTo review recent data about the study of the immune response in sporotrichosis and recent progress in the development of an effective human and feline vaccine.Recent FindingThe cell wall ofSporothrix is an important source of antigens with the potential to develop vaccines. A major candidate is a 70-kDa glycoprotein (gp70). Our group developed a model of sporotrichosis treatment using the monoclonal against gp70 (mAbP6E7) with good results. We also recently developed a humanized antibody, mAbP6E7, that increased phagocytosis in human monocytes and reduced the fungal burden in a murine model of sporotrichosis. The other importance the study demonstrated is the protective capacity of an enolase-based vaccine and Montanide ™ Pet Gel A (PGA) as an adjuvant againstS. schenckii. The use of an immunoproteomic approach demonstrated the efficacy of three peptides as a vaccine to promote a protective immune response against sporotrichosis that aid the development of novel therapeutic approaches against fungal infections.SummarySeveral diseases have been eradicated with the use of vaccines, but the development of vaccines against fungal infections in humans and animals remains a challenge, in part due to a lack of knowledge about the mechanisms of protective immunity against fungal infections and the genetic complexity of fungi. In this review, we discuss recent advances in vaccine development against sporotrichosis.
Source: Current Tropical Medicine Reports - Category: Tropical Medicine Source Type: research